Research programme: purinoceptor P2X3 antagonists - NEOMED

Drug Profile

Research programme: purinoceptor P2X3 antagonists - NEOMED

Alternative Names: BLU-5937; NEO-5024; NEO-5937; P2X3 receptor antagonists - NEOMED

Latest Information Update: 20 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator AstraZeneca
  • Developer NEOMED
  • Class Analgesics; Imidazoles; Pyridines; Small molecules
  • Mechanism of Action Purinergic P2X3 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Cough; Pain; Visceral pain
  • No development reported Interstitial cystitis

Most Recent Events

  • 08 Nov 2017 BELLUS Health announces intention to submit CTA to Health Canada for Cough in the second quarter of 2018
  • 08 Nov 2017 BELLUS Health plans a phase I trial of BLU 5937 in the third quarter of 2018
  • 18 Sep 2017 Pharmacodynamic data from preclinical studies in Cough released by BELLUS Health
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top